Found 6 matching trials
Trial of PDE4 Inhibition With Roflumilast (ARQ-154) Foam 0.3% for the Management of Seborrheic Dermatitis (STRATUM)
PHASE3This phase 3, double-blind, vehicle-controlled study assessed the safety an...
Location
Arcutis Biotherapeutics Clinical Site 01
Long-Term Safety of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
PHASE2This is an open-label, long-term safety study of roflumilast ARQ-154 foam 0...
Location
Arcutis Biotherapeutics Clinical Site 59
Safety and Efficacy of ARQ-154 Foam in Adolescent and Adult Subjects With Scalp and Body Psoriasis
PHASE2This study will assess the safety and efficacy of ARQ-154 foam vs placebo a...
Location
Arcutis Biotherapeutics Clinical Site 71
Topical Roflumilast to Treat Scalp and Body Psoriasis (ARRECTOR)
PHASE3This was a parallel group, double blind, vehicle-controlled study to assess...
Location
Arcutis Biotherapeutics Clinical Site 01
Safety and Efficacy of ARQ-154 Foam in Subjects With Seborrheic Dermatitis
PHASE2This was a parallel group, double blind, vehicle-controlled study assessed ...
Location
Arcutis Biotherapeutics Clinical Site 19
Maximal Usage Pharmacokinetics and Safety Study of ARQ-154 Foam 0.3% in Pediatric Participants With Scalp and Body Psoriasis
PHASE1This study will evaluate the systemic exposure and characterize the plasma ...
Location
Arcutis Clinical Study Site 106